Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging roles of allosteric modulators in the regulation of protein‐protein interactions (PPIs): A new paradigm for PPI drug discovery
Duan Ni, Shaoyong Lu, Jian Zhang
Medicinal Research Reviews (2019) Vol. 39, Iss. 6, pp. 2314-2342
Closed Access | Times Cited: 89

Showing 1-25 of 89 citing articles:

Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions
Xuefei Wang, Duan Ni, Yaqin Liu, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 104
Sequence-based drug design as a concept in computational drug design
Lifan Chen, Zisheng Fan, Jie Chang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 57
Structure-Based Stabilization of Non-native Protein–Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design
Shanmeng Lin, Shih‐Chao Lin, Jia-Ning Hsu, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 6, pp. 3131-3141
Open Access | Times Cited: 115
Discovery of cryptic allosteric sites using reversed allosteric communication by a combined computational and experimental strategy
Duan Ni, Jiacheng Wei, Xinheng He, et al.
Chemical Science (2020) Vol. 12, Iss. 1, pp. 464-476
Open Access | Times Cited: 105
Allosteric drugs and mutations: chances, challenges, and necessity
Enrico Guarnera, Igor N. Berezovsky
Current Opinion in Structural Biology (2020) Vol. 62, pp. 149-157
Closed Access | Times Cited: 88
Fight against novel coronavirus: A perspective of medicinal chemists
Sk. Abdul Amin, Tarun Jha
European Journal of Medicinal Chemistry (2020) Vol. 201, pp. 112559-112559
Open Access | Times Cited: 73
Mechanism of allosteric activation of SIRT6 revealed by the action of rationally designed activators
Shaoyong Lu, Ying-Yi Chen, Jiacheng Wei, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 11, Iss. 5, pp. 1355-1361
Open Access | Times Cited: 73
Combining Allosteric and Orthosteric Drugs to Overcome Drug Resistance
Duan Ni, Yun Li, Yuran Qiu, et al.
Trends in Pharmacological Sciences (2020) Vol. 41, Iss. 5, pp. 336-348
Closed Access | Times Cited: 69
Strategies for targeting undruggable targets
Gong Zhang, Juan Zhang, Yuting Gao, et al.
Expert Opinion on Drug Discovery (2021) Vol. 17, Iss. 1, pp. 55-69
Closed Access | Times Cited: 62
Small molecules targeting protein–protein interactions for cancer therapy
Defa Wu, Yang Li, Lang Zheng, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 10, pp. 4060-4088
Open Access | Times Cited: 31
Fragment-based drug discovery supports drugging ‘undruggable’ protein–protein interactions
Zhi-Zheng Wang, Xing-Xing Shi, Guang-Yi Huang, et al.
Trends in Biochemical Sciences (2023) Vol. 48, Iss. 6, pp. 539-552
Closed Access | Times Cited: 23
Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications
Yuming Zhang, Lianhai Shan, Wentao Tang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5185-5215
Closed Access | Times Cited: 12
Graph Neural Network Model for Prediction of Non-Small Cell Lung Cancer Lymph Node Metastasis Using Protein–Protein Interaction Network and 18F-FDG PET/CT Radiomics
Hyemin Ju, Kangsan Kim, Byung Il Kim, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 698-698
Open Access | Times Cited: 7
Drugging K-RasG12C through covalent inhibitors: Mission possible?
Duan Ni, Xinyi Li, Xinheng He, et al.
Pharmacology & Therapeutics (2019) Vol. 202, pp. 1-17
Closed Access | Times Cited: 70
<p>Current Challenges and Opportunities in Designing Protein–Protein Interaction Targeted Drugs</p>
Woong‐Hee Shin, Keiko Kumazawa, Kenichiro Imai, et al.
Advances and Applications in Bioinformatics and Chemistry (2020) Vol. Volume 13, pp. 11-25
Open Access | Times Cited: 54
Along the allostery stream: Recent advances in computational methods for allosteric drug discovery
Duan Ni, Zong‐Tao Chai, Ying Wang, et al.
Wiley Interdisciplinary Reviews Computational Molecular Science (2021) Vol. 12, Iss. 4
Closed Access | Times Cited: 49
Exploring the Allosteric Territory of Protein Function
Wei-Ven Tee, Zhen Wah Tan, Keene Lee, et al.
The Journal of Physical Chemistry B (2021) Vol. 125, Iss. 15, pp. 3763-3780
Closed Access | Times Cited: 41
Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence
Miquel Duran‐Frigola, Marko Cigler, Georg E. Winter
Journal of the American Chemical Society (2023) Vol. 145, Iss. 5, pp. 2711-2732
Open Access | Times Cited: 20
Impact of Allosteric Modulation in Drug Discovery: Innovation in Emerging Chemical Modalities
Bingsong Han, Francesco G. Salituro, María‐Jesús Blanco
ACS Medicinal Chemistry Letters (2020) Vol. 11, Iss. 10, pp. 1810-1819
Open Access | Times Cited: 44
Harnessing Reversed Allosteric Communication: A Novel Strategy for Allosteric Drug Discovery
Jigang Fan, Yaqin Liu, Ren Kong, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 24, pp. 17728-17743
Closed Access | Times Cited: 34
Computational elucidation of allosteric communication in proteins for allosteric drug design
Duan Ni, Yaqin Liu, Ren Kong, et al.
Drug Discovery Today (2022) Vol. 27, Iss. 8, pp. 2226-2234
Closed Access | Times Cited: 26
Medicinal Chemistry Strategies for the Development of Bruton’s Tyrosine Kinase Inhibitors against Resistance
Shan‐Liang Sun, Shi-Han Wu, Ji-Bo Kang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7415-7437
Closed Access | Times Cited: 25
Mechanistic Insights into the Long-range Allosteric Regulation of KRAS Via Neurofibromatosis Type 1 (NF1) Scaffold Upon SPRED1 Loading
Min-Yu Li, Yuanhao Wang, Jigang Fan, et al.
Journal of Molecular Biology (2022) Vol. 434, Iss. 17, pp. 167730-167730
Closed Access | Times Cited: 22
ASD2023: towards the integrating landscapes of allosteric knowledgebase
Jixiao He, Xinyi Liu, Chunhao Zhu, et al.
Nucleic Acids Research (2023) Vol. 52, Iss. D1, pp. D376-D383
Open Access | Times Cited: 14
Targeting protein-protein interactions with low molecular weight and short peptide modulators: insights on disease pathways and starting points for drug discovery
Daniela Trisciuzzi, Bruno O. Villoutreix, Lydia Siragusa, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 7, pp. 737-752
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top